Skip to search formSkip to main contentSkip to account menu

efaproxiral

Known as: 2-(4-(((3,5-dimethylanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid, 2-Dacmpp, Efaproxyn 
A synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Review
2009
Review
2009
PurposeTo study the efficacy of whole brain radiotherapy (WBRT) with radiosensitizer in comparison with WBRT alone for patients… 
Highly Cited
2008
Highly Cited
2008
A safe, functional-group-tolerant and high-throughput version of the trimethylaluminium mediated amide bond formation reaction… 
Highly Cited
2007
Highly Cited
2007
Objective:To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves quality of life and quality of… 
2007
2007
Abstract Hou, H., Khan, N., Grinberg, O. Y., Yu, H., Grinberg, S. A., Lu, S., Demidenko, E., Steffen, R. P. and Swartz, H. M. The… 
Highly Cited
2006
Highly Cited
2006
  • J. Suh, B. Stea, E. Shaw
  • Journal of clinical oncology : official journal…
  • 2006
  • Corpus ID: 21005938
PURPOSE To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves survival in patients with brain… 
Review
2006
Review
2006
Opinion statementThe development of brain metastases is often viewed as the end stage of a disease course and engenders… 
2005
2005
PURPOSE Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases tissue pO2. We… 
2004
2004
  • J. Suh
  • Expert opinion on investigational drugs
  • 2004
  • Corpus ID: 22624281
Efaproxiral (RSR13) is a synthetic allosteric modifier of haemoglobin that reduces its oxygen binding affinity. By facilitating… 
Highly Cited
2002
Highly Cited
2002
PURPOSE The objectives of this phase II study were to determine survival, safety, pharmacokinetics (PK), and pharmacodynamics (PD…